{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.9","upperLimit":"5.7","value":"3.7"},{"groupId":"OG001","lowerLimit":"1.9","upperLimit":"8.5","value":"3.7"}]}],"title":"RECIST v1.1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.7","upperLimit":"10.3","value":"6.5"},{"groupId":"OG001","lowerLimit":"2.5","upperLimit":"19.4","value":"8.5"}]}],"title":"irRECIST"}],"denoms":[{"counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"38"}],"units":"Participants"}],"description":"TTP was the time to objective progression. Objective progression was defined as 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm. TTP was analyzed by the Kaplan-Meier approach for each tumor type.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with NSCLC received PF-06801591 300 mg SC every 4 weeks for 28-day cycles. (maximum of 851 days)","id":"OG000","title":"Part 2: PF-06801591 300 mg (SC) for NSCLC"},{"description":"Participants with UC received PF- 06801591 300 mg SC every 4 weeks for 28-day cycles. (maximum of 841 days)","id":"OG001","title":"Part 2: PF-06801591 300 mg (SC) for UC"}],"paramType":"MEDIAN","populationDescription":"Analysis population included all the randomized participants who received at least 1 dose of study medication, had measurable disease baseline assessment (within 28 days prior to study entry) and at least 1 post baseline assessment or disease progression, global deterioration of health status, or death.","reportingStatus":"POSTED","timeFrame":"Baseline up to end of treatment in Part 2 (maximum of 851 days)","title":"Time to Progression (TTP) Based on RECIST Version 1.1 and irRECIST - Part 2","type":"SECONDARY","unitOfMeasure":"Months"}